Introduction
The European Society of Human Reproduction and Embryology (ESHRE) Preimplantation Genetic Diagnosis (PGD) Consortium was established in 1997. Since 1999, 10 data collections of PGD for autosomal and sex-linked monogenic diseases and chromosome abnormalities, preimplantation genetic screening (PGS) and social sex selection have been published (ESHRE PGD Consortium Steering Committee, 1999 , 2000 Sermon et al., 2005 Sermon et al., , 2007 Harper et al., 2006 Harper et al., , 2010b Harper et al., 2008b; Goossens et al., 2008) . This report summarizes data XI collected for the calendar year 2008 and the subsequent pregnancies. Data XI also includes the delivery rate for each indication. Cleavage aspiration  656  409  1013  1074  299  255  3706   Cleavage extrusion  40  27  49  67  5  15  203   Cleavage flow displacement  2  0  2  4  3  0  11   Blastocyst  0  0  9  10  0  0  19   Embryology   COC's  10 461  65 73  16 283  17 501  4225  3774  58 817   Inseminated  8710  5581  13 859  15 216  3481  3296  50 143   Fertilized  5910  4078  9863  11 208  2417  2383  35 859   Biopsied  4136  3101  7536  8719  1688  1888  27 068   Successfully biopsied  4081  3067  7428  8608  1670  1866  26 720   Diagnosed  3689  2831  6912  8062  1543  1736  24 773   Transferable  1402  828  1373  1558  681  543  6385   Transferred  949  606  1113  1266  466  375  4775   Frozen  178  78  77  87  69  63  552 Results An overview of all cycles collected previously in data collections I -X can be found in Table Ia , while an overview of the current data collection can be found in Table Ib. For all indications for PGD/PGS, ICSI was the most often used method of fertilization and cleavage-stage aspiration was the most commonly used method of biopsy. Overall zona pellucida drilling was more commonly performed using a laser (Table Ib) . Tables IIa and IIb summarize the 774 cycles to OR collected for data collection XI, a total number that is slightly higher than the previous year (729). In 17 cycles, PGD/PGS was simultaneously performed for an additional fluorescence in situ hybridization (FISH) indication and in 4 cycles PGD was simultaneously performed for an additional PCR indication. As for all years, data XI showed that PGD for reciprocal translocations was performed more often than for Robertsonian translocations or any other type of chromosome abnormality.
PGD cycles for chromosomal abnormalities
For reciprocal translocations, the number of cycles performed for female carriers equals that for male carriers, whereas for Robertsonian translocations, the majority (72%) is performed for male carriers.
Overall, half of the cycles are performed for infertile patients. The rate of infertility ranged from 20% in the group with chromosomal deletions up to 72% as observed in the groups with either sex chromosome aneuploidies and/or Robertsonian translocations carried by the male partner.
In 78% of all cycles, ICSI was used for fertilization, indicating its use for reasons other than male infertility.
The use of laser drilling for zona breaching is still increasing and covers two-thirds of all cycles in data XI.
Aspiration of blastomeres from cleavage stage embryos remains the preferred biopsy method (91%).
For data XI, 9807 oocytes were collected, a mean of 12.7 per cycle (range: 10.2 for sex chromosome aneuploidy to 14.6 for deletions). Of these, 59% (5802/9807) were fertilized (2 pronuclei) and 78% (4513/5802) of the resulting embryos were biopsied. Of the embryos successfully biopsied, 93% (4132/4452) gave a diagnostic result, of which only 27% (1123/4132) were transferable. As expected, the lowest percentage of transferable embryos was found in the reciprocal translocation group (19.8%), whereas generally 4 out of 10 embryos were transferable in the sex chromosome aneuploidy and inversion group. Of all transferable embryos, two-thirds were actually transferred and 15% were frozen. 
PGD for monogenic diseases
Tables IVa and IVb summarize the 4733 and 1363 cycles to OR collected for data collections I -X and XI, respectively. All the monogenic diseases for which PGD was performed in the current data collection (XI) are listed in Supplementary data, Table SIVc . For data XI, the most common indications for PGD for autosomal recessive diseases were b-thalassemia and/or sickle cell syndromes (118 cycles plus 85 cycles for b-thalassemia and/or sickle cell syndromes with HLA compatibility, see below), cystic fibrosis (CF; 126 cycles and 2 cycles for CF and a second indication) and spinal muscular atrophy (SMA; 40 cycles and another 2 for SMA and a second indication). Amongst the autosomal dominant diseases, the most PGD cycles were performed for myotonic dystrophy type I (DM1) (126 cycles plus 2 cycles for DM1 and a second indication), Huntington disease (HD) (117 cycles plus 1 cycle for HD and a second indication), neurofibromatosis (42 cycles plus 2 cycles for neurofibromatosis 1 and a second indication) and familial adenomateous polyposis coli (30 cycles). For a specific diagnosis of X-linked diseases, the most common indications were for fragile X syndrome (110 cycles), Duchenne and Becker muscular dystrophy (30 cycles and 7 cycles, respectively) and haemophilia A and B (18 cycles and 2 cycles were for haemophilia A combined with a second indication). There were 32 cycles for HLA compatibility typing only and 106 cycles for HLA typing along with a specific disorder. The most common indication here was b-thalassemia/sickle cell anaemia (85 cycles). The total number of cycles with HLA typing has slightly decreased from 180 cycles in data X to 138 cycles in the current data collection.
For data XI, ICSI was used in the majority of cycles (99.5% of cycles to OR) and PCR was the most widely used method of DNA amplification (94.4% of cycles to OR). Whole genome amplification followed Overall, the number of PGD cycles performed for monogenic disorders between January and December 2008 further increased by 13% compared with data collection X. There were no marked changes with respect to the progress and outcome of cycles, including the embryology, rates of diagnosis and clinical outcome, such as clinical pregnancy and embryo implantation rates (Harper et al., 2010b) . Finally there were two cycles for mitochondrial disorders. One indication was Leigh syndrome, and the cycle ended in a pregnancy and birth of one healthy baby. The second cycle was carried out for mitochondrial myopathy, encephalopathy, lactic acidosis and stroke and did not result in a pregnancy. Tables Va and Vb summarize (Harper et al., 2008a,b) , in the majority of cases these embryos should be replaced without biopsy. In all 3401 cycles to OR, FISH was the method used for analysis in the laboratory. The PGD Consortium recently published a position statement on the use of PGS (Harper et al., 2010a) . All randomized controlled trials (RCTs) to date for PGS using FISH and mainly cleavage-stage biopsy show no improvements in assisted reproduction technology success rates towards achieving healthy pregnancies. The Consortium recommendation was that the use of arrays on either polar bodies or trophectoderm biopsies should be validated and appropriate RCTs performed. The ESHRE PGS Task Force has conducted a pilot into the feasibility of using arrays for polar body biopsy (Geraedts et al., 2010) and is in the process of setting up a multi-centre RCT.
Preimplantation genetic screening
PGD cycles for social sexing Tables VIa and VIb summarize Twin-to-twin transfusion 1 2
Reduction of multiple pregnancies 33
Quadruplet to twin 4
Triplet to twin 11
Triplet to singleton 14
Twin to singleton 4
Continued

Pregnancies and babies
Tables VIIa, IXa, IXb, Xa, Xb, XIa and b and Supplementary data, Table SXIIa summarize the pregnancy and baby data. Data XI is comparable to previous data collections. Data XI included 1418 clinical pregnancies (Table VIIb) . There were 950 deliveries of 1169 babies. Of the 1117 cycles ending in a pregnancy with a positive heartbeat, follow-up data on 1109 pregnancies were reported. Of the 950 pregnancies reported to have ended with a delivery (with a total number of 1169 babies), neonatal data on 1016 babies were submitted. The delivery rates per indication are reported in Tables IIb, IIIb , IVb, Vb and VIb. Caesarean section was performed for 48% of the deliveries (429/891) ( Table IXb) . In 12 cases, the method of delivery was not known. Confirmation of the diagnosis was performed prenatally (386/732) and/or post-natally (346/732) ( Table Xb) . Table Xb and Supplementary data, Table SXIIb show the abnormalities found during pregnancy or post-natally. Several abnormalities were found that were not related to the PGD.
This report again confirms that pregnancies and babies born after PGD are very similar to the pregnancies obtained and babies born after ICSI treatment (Bonduelle et al., 2002) . In our series, the number of multiple pregnancies remains high (255/1117, 23%), which indicates that 37% (432/1169) of all babies born are part of a multiplet at birth (Table VIIb) Misdiagnoses Table XIIIa summarizes the misdiagnoses reported for data I -X. For data XI, as for data X, no misdiagnoses were reported. The Consortium has published a paper on the possible causes of misdiagnosis in PGD (Wilton et al., 2009) . In addition, the Consortium is currently working on two studies looking at follow-up testing of untransferred embryos (Study 1 for amplification-based testing, Study 2 for FISH-based testing). The eventual publications from these studies should further elucidate the pitfalls of testing single or only a few cells from preimplantation embryos. Figure 1 shows the pregnancy rate for each centre for data XI. The pregnancy rate ranges from 0 to 100% with the average being 21.27%. Although it could be expected that centres carrying out lower numbers of cycles may have lower rates owing to less experience, the findings indicate that some of the most active centres fall below the average 21.27% pregnancy rate and even have pregnancy rates lower than some of the centres performing few cycles.
Success of individual centres
Discussion
This 11th Continued subsequent pregnancies and babies. This is most likely a function of slightly fewer centres supplying data (four less centres submitted data for Collection XI). There were still two levels of membership of the Consortium; full membership for centres who submit annual data and associate membership for centres who cannot submit data (including new clinics, IVF units who work with a diagnostic laboratory that is a member of the Consortium). Associate centres performing PGD must send in summary data. For data XI, very few associate centres (4) sent in summary data and so these data were not included in this report. Most associate centres are satellite PGD centres that work with many IVF centres and they have reported that they cannot obtain information about the IVF cycles. Therefore, we have amended the information we will collect from associate centres to just include basic data on the diagnosis. The Consortium is aware that these satellite centres can send in more extensive data than only the summary data but most of the time not the complete data (as do full members). Therefore, the category 'transport members' has to be adopted. The data requested from these centres need to be set for future data collections. TOP of two fetus of a triplet because of misdiagnosis (unspecified). These two fetuses were monozygotic, the third fetus of the triplet was ongoing and resulted in the term birth of a healthy male (AS repeated IVF failures ESHRE PGD Consortium data collection XI As always, the centres who submit data have access to the raw data, while the associate centres will be allowed to participate in the annual Consortium meetings and they are sent the quarterly Consortium newsletter.
Besides data collection, the Consortium is involved with a number of activities through the working groups.
There are five Working Groups within the PGD Consortium: Molecular Methods (Chair Francesco Fiorentino), Misdiagnosis and Monitoring (Chair Jan Traeger-Synodinos), Accreditation (Chair Katerina Vesela), Database (chair Céline Moutou) and Array-Based PGD (Chairs Dagan Wells and Leeanda Wilton). The Molecular Methods working group continues to develop a database of primers and protocols to aid Full and Transport Member laboratories in developing custom PGD testing methods for patients desiring testing for monogenic disorders. The Misdiagnosis and Monitoring working group continues to work on publication of the follow-up data from amplification-based and FISH-based PGD tests. This paper will be a landmark paper discussing the follow-up of untransferred embryos following PGD testing. The Accreditation working group held a very successful workshop in conjunction with Eurogentest in Athens, Greece entitled Towards Accreditation of a PGD Laboratory. Another workshop of the same name will be held next year in Istanbul in the Fall. The Database working group is still working on an online version of the current database in order to facilitate the input of PGD data for the centres. They also work on a statistical paper covering all data collections since the beginning of the PGD Consortium. ESHRE are considering to support an official guidelines document for Array-Based PGD, a proposal was submitted to the Executive Committee. The working group for this guideline is being developed at the moment. Also from the Array-Based PGD working group, a new external quality assessment (EQA) scheme is being developed to assess array-based PGD testing quality around the world. This EQA, following a pilot study, will be open to any laboratories using array-based technology to assess aneuploidy in human embryos.
Four updated ESHRE Guidelines on the Best Practice in PGD were published in 2011 (Harton et al., 2011a,b,c,d) . These Guidelines cover individual portions of PGD, including Set Up and Organization of a PGD centre, Amplification-based PGD, FISH-based PGD and Embryology as it relates to PGD and PGS. As noted above, a new Guidelines group is being developed now to offer advice on the best practice on array-based PGD.
From the 10 data collections, the Consortium now has detailed data on 33 271 cycles and 5063 babies born after PGD/PGS.
The large amount of detailed information which the Consortium has collected is unique and studies are underway to analyse many aspects of the data in more depth. ESHRE PGD Consortium data collection XI
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